ABSTRACT
INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) is a potentially life-threatening disorder caused by repetitive narrowing and occlusion of the upper airway during sleep, and it has been associated with loud snoring and apnea. OSAS is considered to be a risk factor for hypertension, ischemic myocardial diseases and cerebral vascular diseases [1, 2] , and it is also considered to be a cause of traffic accidents due to sleepiness in the daytime [3, 4] .
Recently, conservative treatments such as nasal continuous positive airway pressure (NCPAP) and oral appliance (OA) therapy have been used as primary treatment for OSAS. NCPAP has become the prime choice because of its safety and effectiveness, though therapeutic compliance is not high because of the sense of incompatibility of the device used in this therapy and difficulty in handling the device. Reports on OA therapy as an alternative to NCPAP began to appear in the 1980s. Crossover studies comparing OA therapy and NCPAP [5] [6] [7] [8] [9] have generally shown OA therapy to be less effective (15% -55% therapeutic success rates) than NCPAP. According to clinical guidelines for the treatment of snoring and obstructive sleep apnea with an OA advocated by the American Sleep Disorders Association [10] , OA therapy is indicated for treatment of patients with primary snoring or mild OSAS. OA therapy may also be indicated for treatment of patients with moderate or severe OSAS who refuse NCPAP treatment. OA therapy is probably perceived as being less intrusive and less disruptive to personal life than NCPAP [11] [12] [13] [14] . Severity of OSAS is considered to be one of prognostic predictors of OSAS in patients receiving OA therapy, but other variables such as skeletal pattern, age and degree of obesity also affect treatment outcomes. The aim of this study was to identify independent prognostic predictors of the efficacy of OA therapy for OSAS.
SUBJECTS AND METHODS

Subjects
The medical records of patients in whom OSAS had been treated with an OA in the Clinic for Snoring and Obstructive Sleep Apnea of the Department of Oral and Maxillofacial Surgery, Niigata University Medical and Dental Hospital were reviewed and a retrospective cohort study was performed. The subjects consisted of 89 patients (77 males and 12 females) with complete set of data. The mean age of the subjects was 52.4 years (range: 20 to 78 years), and mean body mass index (BMI) was 23.9 kg/m 2 (range: 17.3 to 32.2 kg/m 2 ). All patients gave informed consent to the OA therapy and the study was conducted in accordance with the Helsinki Declaration.
Oral Appliance (OA)
In our clinic, a mono-block type mandibular advancement device (Figure 1 ) has been used for OA therapy in patients with mild OSAS and in patients with moderate or severe OSAS who could not continue the NCPAP. Patients were first examined to confirm that they did not have many missing teeth, advanced periodontitis or symptoms of temporomandibular disorder. The appliance was initially fabricated at 50% -70% of the patient's maximal protrusive position of the mandible and titrated to the position where the patient or bed partner noticed a subjective improvement and there were no side effects such as temporomandibular symptoms or tooth pain.
Epworth Sleepiness Scale
Subjective excessive daytime sleepiness was screened by the Epworth sleepiness scale (ESS) [15] , which is a selfadministered questionnaire with eight items.
Cephalometric Analyses
Lateral cephalograms of the subjects were taken with the Frankfort horizontal plane (FH plane) parallel to the floor and with the patient in a centric occlusion. The cephalograms were traced to identify landmarks of hard and soft tissues (Figure 2) . The measuring points were digitized as two-dimensional coordinate values to calculate 15 angles (Figure 3 ), 15 distances (Figure 4 ) and 5 area measurements ( Figure 5 ) by means of a computerized program (CephaloMetrics A to Z Ver.12; YASU-NAGA Computer Systems Co., Inc., Fukui).
Arterial Oxygen Saturation with Pulse Oximetry Inspection When Sleeping
Arterial oxygen saturation was measured overnight with pulse oximetry before treatment and several months after titration of OA therapy, and lowest SpO 2 during the measurement period and CT90 (cumulative percentage time at SpO 2 below 90% during the measurement period) were calculated.
Overnight Polysomnography
Overnight polysomnography (PSG) was performed before treatment and several months after titration of OA therapy, and apnea-hypopnea index (AHI: sums of counts of apnea and hypopnea per hour of sleep) and arousal index (number of spontaneous arousals multiplied by number of hours of sleep) were calculated. This examination was conducted in our hospital or cooperating medical institutions.
Criteria of Effectiveness
OA therapy was considered effective if AHI several months after titration was under 15 events/h and was reduced to at least 50% of that before treatment.
Statistical Analysis
Data including patient age, sex, BMI, and results of cephalometric analyses, ESS and pretreatment PSG were analyzed statistically and multivariate logistic regression analysis was performed to clarify independent prognostic predictors of the efficacy of OA therapy for OSAS. The medians of relevant variables were set to cut-off values, and the variables were assigned to two groups. Odds ratios (ORs) were calculated to evaluate associations between the variables and the therapeutic effect, and univariate analysis was performed. The extent of intercorrelation among the variables was considered by Spearman's rank correlation coefficient, and valuables without high intercorrelation were selected. Explanatory variables were extracted by performing logistic regression analysis using the stepwise procedure, and the forecast Figure 1 . Mono-block type oral appliance used in present study.
S:
Center of sella turcica. N:
Most anterior point of the frontonasal suture. Or:
Lowest point on the average left and right inferior borders of the bony orbit. Po:
Highest point on the superior surface of soft tissue of the external auditory meatus. Pt:
Pterygoid point. R:
Root of pharynx. Ba:
Midpoint of the anterior border of the foramen magnum.
Ar:
Intersection between the external contour of the cranial base and the dorsal contour of the condylar head or neck. Xi:
Geometric center of the ramus of the mandible. ANS: Apex of the anterior nasal spine. PNS: Intersection between the nasal floor and the posterior contour of the maxilla. A:
Most posterior point on the anterior contour of the upper alveolar process. B:
Most posterior point on the anterior contour of the lower alveolar process. PM:
Protuberance menti. Pog:
Most anterior point of the contour of the chin.
Gn: Point on the chin determined by bisecting the angle formed by the facial and mandibular planes. Me:
Most inferior point on the mandibular symphysis. Go:
Most posterior-inferior point on the convexity of the angle of the mandible. H:
Most anterior-superior point on the body of the hyoid bone. Eb:
Most anterior-inferior point of the epiglottic fold. Et:
Tip of the epiglottis, the most superior point of the epiglottis. P:
Lowest point of the soft palate. TT:
Most anterior point of the tip of the tongue. TH:
Farthest point on the tongue dorsum from the TT-Eb line. Mo:
First molar contact point. C4:
Fourth cervical vertebra, the most anterior inferior point of it.
Cv2ig: Tangent point at the superior, posterior extremity of the odontoid process of the second cervical vertebra. Cv2ip: Most inferior-posterior point on the corpus of the second cervical vertebrae. Cv4ip: Most inferior-posterior point on the corpus of the fourth cervical vertebra. 
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TGL:
Distance from Eb to TT.
TGH:
Distance from TH to TT-Eb line.
PNS-P:
Distance from PNS to P.
MPT:
The maximum thickness of the soft palate measured on a line perpendicular to the PNS-P.
SPAS:
The thickness of the airway behind the soft palate along a line parallel to Go-B.
MAS:
The thickness of the airway along a line parallel to Go-B through P.
IAS:
The thickness of the airway along a line extended through Go-B. The area confined by the outline of the soft palate that starts and ends at PNS through P.
B Oropharynx:
The area outlined by the inferior border of the nasopharynx, the posterior surface of the soft palate and tongue, a line parallel to the palatal plane through point Et, and the posterior pharyngeal wall.
C Tougue:
The area outlined by the dorsal configuration of the tongue surface and lines that connect TT, RGN, H, and Eb.
D Nasopharynx:
The area outlined by a line between R and PNS, an extension of the palatal plane to the posterior pharyngeal wall.
E Hypopharynx:
The area outlined by the inferior border of the oropharynx, the posterior surface of the epiglottis, a line parallel to the palatal plane through point C4, and the posterior pharyngeal wall. equation of the efficacy of OA therapy was also calculated. All statistical analysis was carried out with SPSS for Windows, version 11.0 (SPSS Inc., Chicago, USA).
and non-responder group were 21.0 events/h (range: 5.3 to 67.5 events/h) and 20.3 events/h (range: 7.2 to 43.7 events/h), respectively. There were no statistically significant differences in age, BMI and AHI before treatment between the two groups. After OA titration, the mean AHI value in the responder group decreased to 4.9 events/h (range: 0.2 to 10.9 events/h), which was significantly smaller than the value of 16.9 events/h (range: 7.4 to 41.6 events/h) in the non-responder group by the Mann-Whitney test (p < 0.001) ( Table 1) .
RESULTS
OA therapy was effective for 59 patients (50 males and 9 females) who constituted the responder group. The mean age of the responder group was 51.4 years (range: 20 to 78 years), and that of the non-responder group (27 males and 3 females) was 54. (Tables 2-6 ). LFH and McN-A were then selected as independent prognostic predictors of the efficacy of OA therapy by multivariate stepwise logistic regression analysis (likelihood ratio test) ( Table 7) , and the following forecast equation was obtained:
The positive reaction predictive value was 78.2% and the negative reaction predictive value was 68.4%. Overall predictive value for OA therapy was 74.2%.
DISCUSSION
The prevalence of OSAS in Japanese is probably about 2% and the prevalence of snoring in Japanese is about 13% [16] . Factors that cause obstruction of the upper airway include anatomical factors and functional factors, and anatomical factors such as obesity and craniofacial deformity are thought to play a major role [17] [18] [19] . In our previous studies [20, 21] , obesity rate in the population of Japanese OSAS patients was lower than that in the population of westem OSAS patients and a large number of Japanese OSAS patients had short mandibular body and/or mandibular retrusion. Therefore, Japanese people are thought to be a race in which OSAS can develop easily due to skeletal factors.
In the recent treatment strategy for OSAS, conservative treatments such as NCPAP or OA therapy have been used as the primary treatment. OA therapy may be a first-line choice in treatment of patients with mild OSAS [10] and may also be considered in patients with moderate or severe OSAS who could not continue the NCPAP. A mandibular advancement device was reported to have a more potent effect for OSAS than other types of OA. This device maintains the anterior position of the mandible during sleep and prevents oropharyngeal airway obstruction indirectly by moving the suprahyoid and genioglossal muscles anteriorly [22] . It was suggested that forward and inferior displacement of the mandible decreases the gravitational effect of the tongue in the supine position [23] and enlarges the velopharynx by stretching the palatoglossal and palatopharyngeal arches [24, 25] . In our clinic, a mono-block type mandibular advancement device has been used because the device is simple and economical.
Research data concerning OA therapy have been accumulating over the past decade, but the characteristics of patients who would benefit from OA therapy have not been determined sufficiently. Efficacy rates of OA therapy for OSAS in previous studies have varied from 50% to 80% depending on the definition of success [26] [27] [28] [29] . In the present study, OA therapy was effective for 73.7% of the patients when responders were defined as patients showing at least 50% reduction in AHI compared with that before treatment and an AHI < 15 events/h when using an OA. Because of this limitation in effectiveness, researchers have tried to determine whether pretreatment parameters can predict outcomes of OA therapy. Although some authors could not identify cephalometric variables as prognostic predictors of the efficacy of OA therapy for OSAS [27, 30] , others reported correlations between outcomes of OA therapy and cephalometric variables [31] [32] [33] [34] [35] [36] [37] [38] [39] . Eveloff et al. [31] found a significantly smaller mandible-hyoid bone distance in responders to OA therapy than in nonresponders and they also reported that AHI after OA titration could be predicted by baseline AHI and four cephalometric variables(SNA, posterior airway space, mandibular-hyoid distance, and posterior facial height). Mehta et al. [36] formulated a congeneric model for outcome prediction of OA therapy using baseline AHI, neck circumference, and two cepha-lometric variables. Liu et al. [37] used percentage change in AHI to classify subjects into good, moderate, and poor responder groups and they reported that OA therapy is more effective in younger and less obese patients with long maxilla, small oropharynx, smaller overjet, less erupted maxillary molars, and large ratio of vertical airway length to cross-sectional area of the soft palate. Marklund et al. [34] reported that reduction of AHI using an OA is associated with normal mandibular plane angle and small anterior lower anterior facial height. Skinner et al. [40] reported that increased mandibular-hyoid distance is the only cephalometric variable associated with a good clinical outcome of OA therapy. Hoekema et al. [38] reported that the outcome of OA therapy was favorable, especially in less obese patients with mild sleep apnea and mandibular retrognathism. Andrew [39] reported that larger SNMP, which is the angle between the cranial base and the mandibular plane, was the only cephalometric variable related to the efficacy of OA therapy. In the present study, multivariate logistic regression analysis demonstrated that wider LFH and larger McN-A were independent prognostic predictors for clinical outcomes of OA therapy. These results indicate that OA therapy is more effective in patients with large anteroposterior diameter of the maxilla and large lower facial height. Although there are some conflicting reports on prognostic predictors of OA therapy [37] , we think that the oropharyngeal airway and tongue space may not be enlarged effectively by the use of an OA in patients with small anteroposterior diameter of the maxilla and small lower facial height.
This study had several limitations. A lateral cephalogram is a two-dimensional representation of three-dimensional structures, which was obtained in an awake state and an upright position, but this imaging technique has the advantages of low cost, convenience, stability and minimal radiation compared to three-dimensional (3D) imaging using MRI or CT. However, analyses of 3D imagings may be needed to make accurate assessments of threedimensional maxillofacial morphology and oropharyngeal airway space. Moreover, neuromuscular functional analysis may be needed to clarify functional factors. Even so, the positive reaction predictive value of the prediction formula in this study was 78.2%, which exceeded the true response rate, and the negative reaction predictive value was 66.7%, which exceeded the true invalid coefficient. The overall predictive value for OA therapy was 74.2%, which is of sufficient accuracy for clinical use.
CONCLUSION
The results of this study suggested that nonresponders have small anteroposterior diameter of the maxilla and small lower facial height and that the independent prognostic predictors of the efficacy of OA therapy for OSAS are LFH and McN-A of cephalometric measurements. The overall predictive value for OA therapy by multivariate logistic regression analysis was 74.2%, which is of sufficient accuracy for clinical use.
